A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001
An Open Label Long Term Follow up Study for Patients With Melanoma Who Were Previously Enrolled in the Phase I Study IMM-101-001
Sponsor: Immodulon Therapeutics Ltd
Terminated
Sponsor considered no further meaningful data was being collected, nor were likely to be collected in the future.
Other terminated trials from Immodulon Therapeutics Ltd
More terminations from Immodulon Therapeutics Ltd
A PHASE1/PHASE2 clinical study on Malignant Melanoma, this trial is terminated or withdrawn. The trial is conducted by Immodulon Therapeutics Ltd and has accumulated 11 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Terminated PHASE1_PHASE2
Status: Completed → Terminated
-
Jan 2021 — Jun 2023 [monthly]
Completed PHASE1_PHASE2
▶ Show 6 earlier versions
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Nov 2018 — Aug 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Mar 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Unknown Status → Active Not Recruiting
-
Feb 2017 — Mar 2017 [monthly]
Unknown Status PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE1_PHASE2
First recorded
Feb 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Immodulon Therapeutics Ltd
For direct contact, visit the study record on ClinicalTrials.gov .